Press releasePRNewswire
Inhibrx Biosciences
INBX · NASDAQ
$95.30+$5.51 (+6.14%)TodayMarket closed ·
Prev close $89.79
Latest news
- NewsVandana Singh
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
- Press releasePRNewswire
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
- Press releasePRNewswire
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
- Press releasePRNewswire
Inhibrx Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
- Press releasePRNewswire
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
- Press releasePRNewswire
Inhibrx Reports First Quarter 2026 Financial Results
- NewsVandana Singh
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
- Press releasePRNewswire
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releasePRNewswire
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
- NewsVandana Singh
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Inhibrx Announces Updated Interim Data From Phase1/2 Ozekibart Combination With Folfiri Evaluation
- Press releasePRNewswire
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
- Press releasePRNewswire
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
- Press releasePRNewswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
- Press releasePRNewswire
Inhibrx Announces Participation in Upcoming Scientific Conference
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releasePRNewswire
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
- News
Earnings Scheduled For November 14, 2025
- Press releasePRNewswire
Inhibrx Reports Third Quarter 2025 Financial Results
- Press releasePRNewswire
Inhibrx Announces Participation in Upcoming Scientific Conferences
- NewsAvi Kapoor
US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone
- NewsPiero Cingari
Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
- NewsAvi Kapoor
Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October
- Press releasePRNewswire
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
- Press releasePRNewswire
Inhibrx Reports Second Quarter 2025 Financial Results
- Press releasePRNewswire
Inhibrx Reports First Quarter 2025 Financial Results
- Press releasePRNewswire
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
- Press releasePRNewswire
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.